Loading...
Cassiopea S.p.A.
SKIN.SW•SIX
Healthcare
Biotechnology
CHF35.70
CHF3.20(9.85%)
Swiss Market opens in 0h 29mCassiopea S.p.A. (SKIN.SW) AI-Powered Stock Analysis
See how Cassiopea S.p.A. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCassiopea S.p.A. (SKIN.SW) Stock Overall Grade
Cassiopea S.p.A.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Cassiopea S.p.A.'s overall stock rating.
Forecast
C+Score
50/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Cassiopea S.p.A. (SKIN.SW) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 50/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Cassiopea S.p.A. stock grade, including financials, comparisons, and forecasts.